The potential clinical benefit of routine comprehensive genomic profiling in non-small cell lung cancer for the detection of prognostic co-mutations — A multicenter next generation sequencing study
Routine genetic testing reveals hidden patterns that predict immunotherapy response in lung cancers previously thought untargetable.
In a prospective multicenter study of 437 NSCLC samples undergoing routine NGS panel testing, 70.3% of samples without actionable driver mutations still contained prognostically and therapeutically relevant co-mutations in TP53, STK11, or KEAP1 — all known to modulate immunotherapy response. STK11 exon 1 variants dominated and KEAP1 mutations were mostly VUS, highlighting interpretation challenges and supporting the value of broader NGS panels.
What the study was
- Study design
- Prospective multicenter real-world cohort
- Population
- NSCLC patients undergoing NGS panel testing
- Sample size
- 437
- Category
- Genomics/Precision Medicine
- Maturity
- Validated
- Journal
- Cancer Treatment and Research Communications
Why it surfaced
Prospective multicenter NGS data supporting routine comprehensive genomic profiling in NSCLC for co-mutation detection — directly relevant to clinical practice decisions about immunotherapy eligibility. Cancer Treat Res Commun.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.